Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Cadernos De Saude Publica|June 1, 2022
Impacts of the 2017 Brazilian National Primary Care Policy on public primary health care in Rio de Janeiro, BrazilFabricio Loureiro Garcia, Mariana SocalJournal of Pharmaceutical Policy and Practice|October 14, 2017
Branded prescription drug spending: a framework to evaluate policy optionsJeromie Ballreich, G Caleb Alexander, Mariana Socal, et al.Health Affairs Scholar|February 7, 2025
Increasing competition, improving access, and lowering the cost of naloxone in CaliforniaEmily Estus, Robin Figueroa, Helen Lee, et al.Journal of Managed Care & Specialty Pharmacy|December 28, 2023
Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019Angela Liu, Andrew Xuan, Mariana Socal, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 14, 2026
Impact of Drug Shortages on Medicare Part D Prescription Drugs Inflation RebatesMariana Socal, Yuchen Wang, Jeromie Ballreich, et al.JAMA Network Open|March 18, 2026
Brand Manufacturer Coupons and Pharmaceutical Product HoppingJason B Gibbons, Michael DiStefano, Gerard F Anderson, et al.The American Journal of Managed Care|April 19, 2018
Limited distribution networks stifle competition in the generic and biosimilar drug industriesLaura Karas, Kenneth M Shermock, Celia Proctor, et al.Pharmacotherapy|March 5, 2023
Accelerated approval drug labels often lack information for clinical decision-makingJeromie Ballreich, Mariana Socal, Charles L Bennett, et al.Annals of Internal Medicine|May 23, 2022
Medicare Spending on Drugs With Accelerated ApprovalJeromie Ballreich, Mariana Socal, Charles L Bennett, et al.Health Economics Review|July 12, 2022
Trajectories of prices in generic drug markets: what can we infer from looking at trajectories rather than average prices?Antonio J Trujillo, Jose C Gutierrez, Emmanuel E Garcia Morales, et al.Pageof 1